Human medicinehttps://www.ema.europa.eu/en/homepageHuman medicineen-gbCopyright: (C) European Medicines AgencyWed, 17 Jul 2024 03:48:04 +0200Fri, 05 Jul 2024 15:40:00 +0200Opinion/decision on a Paediatric investigation plan (PIP): Adtralza, Tralokinumab, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Dermatology, PIP number: P/0186/2023https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001900-pip02-17-m07Opinion/decision on a Paediatric investigation plan (PIP): Adtralza, Tralokinumab, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Dermatology, PIP number: P/0186/2023https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001900-pip02-17-m07Fri, 05 Jul 2024 15:40:00 +0200Human medicine